To analyze provisional mortality data for deaths occurring among US residents in 2025 and compare it with 2024 data.
Approach:
Data Analysis: Researchers analyzed provisional death certificate data from the National Vital Statistics System for deaths occurring in 2025, comparing it with final mortality data from 2024.
Statistical Methods: Age-adjusted mortality rates were calculated overall and by sex and race and ethnicity, with statistical significance assessed using z tests.
Key Findings:
In 2025, heart disease remained the leading cause of death, accounting for 694,708 deaths, followed by cancer with 622,832 deaths and unintentional injuries with 184,265 deaths.
The age-adjusted mortality rate was highest among Black people (869.0 per 100,000) and lowest among multiracial people (187.3 per 100,000).
Interpretation:
Provisional mortality data provide an early assessment of national mortality patterns and may guide public health decision-making.
Limitations:
Data are provisional and may change as additional information and updated population estimates become available.
Reporting delays may particularly affect causes of death such as unintentional injuries.
Potential misclassification of race and Hispanic ethnicity on death certificates may impact the accuracy of mortality statistics.
Changes in Census population estimation methods may affect comparisons, particularly for race groups with smaller populations.
Conclusion:
Provisional mortality data indicate a decrease in age-adjusted death rates in 2025.
KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.